Skip to content

Study · Not a test of the peptide alone · 2005

3 results

Complementary secretagogue pairs unmask prominent gender-related contrasts in mechanisms of growth hormone pulse renewal in young adults.

Soares-Welch C, Farhy L, Mielke KL, Mahmud FH, Miles JM, Bowers CY, Veldhuis JD

The Journal of clinical endocrinology and metabolism5 Jan 2005Cited by 11 (Europe PMC)

PMID15634714 (opens in a new tab)PMCIDPMC1289271 (opens in a new tab)DOI10.1210/jc.2004-1365 (opens in a new tab)PepBankPUB-15634714
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 01HumanNot a test of GHRP-2 aloneNon-randomized trialMechanism

    L-arginine plus GHRP‑2 evoked 2.2-fold greater burst-like GH release in young women than in young men.

    In plain wordsAn l-arginine and GHRP‑2 combination caused a 2.2 times larger GH release in young women than in young men.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH release evoked by L-arginine/GHRP-2 in women versus men
    Study

    n = 14

    Comparator
    Men
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Fold difference in burst-like GH release, women versus men
    2.2 fold
    L-arginine/GHRP-2

    Source sentences

    Summary
    2) L-arginine/GHRH and L-arginine/GHRP-2 evoked, respectively, 4.6- and 2.2-fold greater burst-like GH release in women than men (P < 0.001 and P = 0.015)
    1 context sentence
    Summary · context
    we designed dual-effector stimulation paradigms in eight young men and six women

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 02HumanNot a test of GHRP-2 aloneNon-randomized trialMechanism

    GHRH plus GHRP‑2 elicited comparable GH secretion in young women and young men.

    In plain wordsA GHRH and GHRP‑2 combination caused a similar GH release in young women and young men.

    Peptide
    GHRP-2
    Outcome
    No significant changeGH secretion evoked by GHRH/GHRP-2 by gender
    Study

    n = 14

    Comparator
    Men
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    3) GHRH/GHRP-2 elicited comparable GH secretion by gender.
    1 context sentence
    Summary · context
    we designed dual-effector stimulation paradigms in eight young men and six women

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 03HumanNot a test of GHRP-2 aloneNon-randomized trialMechanism

    In young men and women combined, estradiol concentrations positively predicted responses to L-arginine plus GHRP‑2.

    In plain wordsIn young adults, higher estradiol was linked to a larger GH response to an l-arginine and GHRP‑2 combination.

    Peptide
    GHRP-2
    Outcome
    IncreaseEstradiol as predictor of L-arginine/GHRP-2 response
    Study

    n = 14

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    r2
    0.49
    estradiol vs L-arginine/GHRP-2 response

    Source sentences

    Summary
    estradiol concentrations positively predicted responses to L-arginine/GHRP-2 (r2= 0.49, P = 0.005)
    1 context sentence
    Summary · context
    we designed dual-effector stimulation paradigms in eight young men and six women

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.